Similar articles

• Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.

  Montaner JS, Mo T, Raboud JM, Rae S, Alexander CS, Zala C, Rouleau D, Harrigan PR. Montaner JS, et al. J Infect Dis. 2000 Feb;181(2):729-32. doi: 10.1086/315243. J Infect Dis. 2000. PMID: 10669364 Clinical Trial.
• Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.

  Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MM. Kuritzkes DR, et al. J Infect Dis. 2000 Feb;181(2):491-7. doi: 10.1086/315244. J Infect Dis. 2000. PMID: 10669331 Clinical Trial.
• Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.

  Balotta C, Berlusconi A, Pan A, Violin M, Riva C, Colombo MC, Gori A, Papagno L, Corvasce S, Mazzucchelli R, Facchi G, Velleca R, Saporetti G, Galli M, Rusconi S, Moroni M. Balotta C, et al. Antivir Ther. 2000 Mar;5(1):7-14. Antivir Ther. 2000. PMID: 10846586
• Viral resistance: a major challenge in managing HIV disease.

  Boucher CA, Reedijk M. Boucher CA, et al. J Biol Regul Homeost Agents. 1995 Jul-Sep;9(3):91-4. J Biol Regul Homeost Agents. 1995. PMID: 8782014 Review. No abstract available.
• [Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].

  Aguirrebengoa K, Mallolas J, Uriz J, Torres Tortosa M. Aguirrebengoa K, et al. Enferm Infecc Microbiol Clin. 1996 Oct;14 Suppl 1:3-9. Enferm Infecc Microbiol Clin. 1996. PMID: 9053024 Review. Spanish. No abstract available.